Since the beginning of July 2018, the Mediterranean region has experienced an epidemic of West Nile virus infections: 24 cases in three French regions (Paca, Corsica and Occitania), according to the latest report from Public Health France. The disease is transmitted by the Culex mosquito.
As of January 1, 2018, specific reimbursement for pathogen inactivated platelets is now available in Germany.
On October 30, 2017 Cerus Corp. announced that it has entered into a two-year supply contract with Centro de Transfusion de la Comunidad de Madrid (CTCM) for the INTERCEPT Blood System for platelets.
The French Ministry of Health decided late 2016 that platelet pathogen inactivation should be deployed throughout the entire French territory for the control of bacterial infections transmitted by transfusion, following the recommendations of the National Agency for the Safety of Medicines and Health Products (ANSM).
In Europe, 40% of all platelet concentrates undergo either bacterial screening or pathogen inactivation. This percentage may increase even more in 2018 as major European countries are currently taking action to mitigate the risk of septic transfusion reactions and emerging pathogens.